A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Imo State Police Command has arrested two female suspects, Joy Ugwu from Idah, Kogi State and Rosella Michael from Zamba in ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal, showing promise for relacorilant in treating platinum-resistant ovarian cancer. The ROSELLA trial ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Corcept Therapeutics (CORT) announced that Rosella, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary ...

TYLER, Texas (KLTV) - An East Texan celebrated her 101st birthday today at the Wesley House Assisted Living Center in Gilmer. It wasn’t like any other birthday for Rosella Nix, a resident at the ...

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 Corcept Therapeutics Incorporated (NASDAQ: CORT), a ...

In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease progression compared to patients treated with nab ...

The data will be presented in a late-breaking oral presentation on Monday, June 2, 2025. The ROSELLA trial is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F), the European ...

Results will support a New Drug Application (NDA) in the United States and a Marketing Authorization Application (MAA) in Europe Relacorilant plus nab-paclitaxel has the potential to become a new ...